Abstract
Tubal factor infertility remains a major cause of female reproductive dysfunction. Current therapeutic options, such as surgical repair or in vitro fertilization, only bypass but do not restore the dysfunctional uterine tube. Recent advances in tissue engineering and regenerative medicine (TERM) highlight biomaterials and organoid systems as promising tools to regenerate oviductal tissue and thus support natural conception. The manuscript comprehensively reviews 42 studies focused solely on TERM of the uterine tubes. Current status of uterine tube tissue engineering demonstrates that natural polymers, including collagen and decellularized extracellular matrix, provide biocompatible scaffolds capable of mimicking native extracellular environments. Synthetic polymers enable adjustment of mechanical properties and reproducibility, while hydrogels offer a biomimetic 3D microenvironment that supports epithelial differentiation, angiogenesis, and embryo development. Moreover, uterine tube–derived organoids, in which the polymeric component plays a crucial role, provide physiologically relevant in vitro models for studying pathology, drug testing, and translational applications. Recent advances in 3D bioprinting and magnetic bioprinting have enabled the development of artificial uterine tube models that better mimic native tissue architecture and cell organization. These findings underscore the translational potential of biomaterial-based strategies for uterine tube regeneration. Their integration into reproductive medicine may offer novel therapeutic avenues for restoring tubal function, improving fertility outcomes, and advancing patient-specific approaches in the management of female infertility.
Keywords: uterine tubes, regeneration, polymers, fertility, tissue engineering, organoids, 3D bioprinting
Graphical Abstract.
Introduction
The female reproductive system comprises complex anatomical structures responsible for reproduction. The correct interaction and regulation of its major organs, such as the ovaries, uterine tubes, uterus, cervix, and vagina, are essential for maintaining women’s reproductive health 1 . The female reproductive system is responsible for the production of oocytes, the process of fertilization, fetal development, and childbirth. This system functions as a complex network that is directly influenced by endocrine signaling, specifically hormones present in the bloodstream 2 . Endocrine disruptions are directly linked to female fertility dysfunction and can also cause a range of other gynecological conditions, such as polycystic ovary syndrome (PCOS), endometrial hyperplasia, endometriosis, pelvic organ prolapse, reproductive cancers, and so on. In addition, pathologies affecting the women’s reproductive system account for one-third of diseases that have a significant impact on women’s overall health. Unfortunately, their prevalence has been on the rise in recent years 3 . Pharmacological therapy, combined with surgical interventions, represents a conventional treatment approach. However, these strategies often do not yield satisfactory results and can cause adverse side effects 4 . Therefore, there is a pressing need to develop more effective and less harmful therapeutic strategies to preserve normal reproductive physiology in women.
Uterine tubes are 10- to 12-cm-long paired organs of the female reproductive system. They connect the ovaries with the uterus and play a crucial role in the process of fertilization and early embryo development 5 (Fig. 1). The main function of the uterine tubes is to ensure the transport of the oocyte from the ovary to the uterus as well as to provide a suitable environment for fertilization and early embryonic development 6 . Therefore, their patency and functioning epithelium are crucial for successful gameto-maternal interaction 7 . Medical literature describes that 85% of infertile couples have a known cause, and tubal factor infertility accounts for approximately 35% of these cases 8 .
Figure 1.
Anatomy and histology of the female uterine tube. Figure was drawn by authors in PowerPoint.
The gold standard for tubal infertility treatment is in vitro fertilization (IVF). In addition, surgical interventions for restoring tubal patency are often indicated 9 . IVF is described as a widely used assisted reproductive technology that helps to overcome various forms of infertility 10 . The whole process involves several steps (Fig. 2). It starts with controlled ovarian hyperstimulation to induce the development of multiple follicles, followed by transvaginal oocyte retrieval. The next step involves fertilizing retrieved oocytes with sperm in a controlled in vitro environment. Subsequently, embryos are cultured for several days until they reach the blastocyst stage. High-quality embryos are then transferred into the uterine cavity. The technique may also include additional procedures such as intracytoplasmic sperm injection, preimplantation genetic testing, or embryo cryopreservation 11 . Since IVF completely circumvents the uterine tubes, it is considered the preferred therapeutic option for patients with tubal infertility 12 . On the other hand, this approach is costly and may not be suitable for every woman. Factors such as a woman’s age and overall physical as well as psychological conditions need to be considered 13 . In addition, this technique does not solve the problem with the diseased uterine tubes.
Figure 2.
Process of uterine tube organoid formation. This process involves a biopsy of the uterine tube tissue and subsequent isolation (mechanical and enzymatic) of uterine tube epithelial cells. The next step consists of culturing these cells in a specific medium supplemented with various growth factors. To complete differentiation into 3D uterine tube organoids, the cell suspension is embedded in a suitable ECM scaffold (Matrigel), where cells begin to proliferate and self-organize into spheroid organoids. Figure was drawn by authors in PowerPoint.
Despite the implementation of established clinical approaches for tubal infertility, the emergence of TERM offers novel therapeutic possibilities with significant potential not only to address this complex reproductive challenge but also to support the restoration of natural conception. Accordingly, the ability to effectively regenerate oviductal tissue after pathological damage, whether caused by inflammation, hydrosalpinx, malignancies, or ectopic pregnancy, constitutes a key strategy in restoring female reproductive function 14 .
TERM integrates the latest advancements in stem cells, their derivatives, biomaterials, and bioactive molecules to facilitate the restoration of damaged tissues. Among these components, biomaterials have garnered particular interest, as ongoing research and development enable their targeted modification using stem cells, exosomes, or other biologically active agents 15 .
Despite their fundamental role in fertilization and early embryo development, the uterine tubes have long remained underrepresented in reproductive research compared to other gynecological organs, such as the uterus and ovaries. It is challenging to precisely determine this phenomenon. However, pointed-out imbalance may be attributed to several factors, including the anatomical inaccessibility of the oviducts or the historical prioritization of endometrial and ovarian pathologies such as cancer, endometriosis, PCOS, or infertility related to endometrial dysfunction16–19. In addition, advances in assisted reproductive technologies have shifted scientific attention away from restoring tubal function toward bypassing it altogether. Consequently, progress in understanding the biology, regeneration, and pathology of the uterine tubes has lagged, creating a significant knowledge gap that limits the development of targeted therapeutic interventions.
While TERM has been widely explored within the scope of female reproductive health, most research efforts have predominantly targeted organs other than the oviducts. This is why the presented article focuses exclusively on the potential of oviductal tissue engineering, specifically on the application of biomaterials with regenerative capabilities.
Materials and methods
This manuscript presents a comprehensive review of recent advancements in uterine tube TERM, with particular emphasis on the application of biomaterials, organoids, and 3D bioprinting. The literature review was conducted using the PubMed database between 27 June and 30 July 2025, employing search terms including natural polymers, synthetic polymers, hydrogels, organoids, oviducts, uterine tubes, regeneration, 3D bioprinting, as well as their combinations. Additional pertinent publications were identified through other databases, such as Google Scholar and Scopus (Elsevier). Only peer-reviewed articles published in English were included. Publications primarily addressing preclinical or clinical studies relevant to uterine tube regeneration were selected for analysis. Initially, the dataset was screened for duplicates (n = 13), after which all retrieved manuscripts were manually reviewed to verify their accuracy. Although articles primarily focused on other reproductive organs were excluded from the dataset, several selected studies addressing tissue engineering strategies for related organs are mentioned throughout the manuscript to provide broader context and enhance the conceptual completeness of the topic. Duplicates, commentaries, editorials, and conference proceedings without full text were also omitted. Through a screening process, we identified 42 publications exclusively focused on uterine tube TERM and analyzed them in detail. Presented review provides a thorough evaluation of natural and synthetic polymers, hydrogels, organoid systems, and 3D bioprinting, emphasizing their translational potential for promoting uterine tube regeneration and improving female reproductive outcomes.
Results
Biomaterials for uterine tubes regeneration
Uterine tubes are highly specialized and anatomically complex structures that play an essential role in female reproduction, facilitating oocyte capture, fertilization, and early embryo transport 20 . Within the framework of TERM, successful restoration or reconstruction of the oviduct must account for the organ’s distinct regional anatomy, specialized cellular composition, and dynamic physiological environment. Anatomically, the uterine tube is divided into four segments: the infundibulum, ampulla, isthmus, and intramural segment, each exhibiting unique histological architecture and region-specific functional roles. These differences include variations in epithelial cell types, mucosal folding, muscular layering, and ciliary activity 21 . Consequently, the design and selection of biomaterials and scaffolds for uterine tube regeneration should reflect these regional characteristics to support proper physiological function and tissue integration.
Natural biomaterials for uterine tubes regeneration
In tissue engineering, natural polymer-based scaffolds have gained significant attention due to their excellent biological properties, mainly reflected in biocompatibility, bioactivity, biodegradability, and ability to mimic the extracellular matrix (ECM) of the native tissues 22 . In addition, these materials facilitate favorable cell–material interactions, which can further enhance cellular proliferation and promote lineage-specific differentiation 23 . On the other hand, natural polymer-based matrices also exhibit unfavorable characteristics, such as poor mechanical strength and stability due to a rapid biodegradation rate. This might limit their application in dynamic in vivo environments 24 . In addition, their physical and chemical properties are more difficult to adjust. Due to their biological origin, manufacturing inconsistencies and incomplete purification may result in the presence of immunogenic contaminants, potentially causing severe adverse reactions when implanted in vivo 25 . Despite the mentioned limitations, the natural origin and enhanced biocompatibility of these scaffolds represent key advantages. This has driven considerable interest in their use for tissue engineering of the uterine tubes, where biological functionality and host integration are of critical importance. Several preclinical studies have demonstrated the potential of these biomaterials to support cellular adhesion, differentiation, and tissue regeneration in uterine tube models.
Collagen scaffolds
Collagen is the most abundant protein in mammals and a key structural component of ECM. Its widespread use in biomedical applications stems from its excellent biocompatibility and favorable biological properties 26 . Collagen-based scaffolds have consistently demonstrated enhanced cellular responses, including improved cell attachment, migration, proliferation, and differentiation 27 . Moreover, collagen can be easily modified or combined with bioactive molecules to further promote tissue regeneration. However, its practical application is limited by high production costs and rapid biodegradation 28 . These drawbacks can be mitigated by blending with other polymers, particularly synthetic ones, to improve its mechanical stability and control degradation rates 29 . A pioneering study regarding collagen-based scaffolds was conducted by Venkataraman et al. 30 . A collagen matrix was applied to culture rabbit uterine epithelial cells under in vitro conditions. Results showed that collagen matrix supported morphological differentiation into ciliated and secretory cell types, which are crucial for physiological oviductal function.
Decellularized scaffolds
Decellularized scaffolds are obtained from native tissues or organs in which all cellular components have been removed while preserving the structure, composition, and mechanical properties of ECM 31 . Their close biological resemblance to native tissue makes them highly attractive for TERM applications. In addition, they are biocompatible and support neovascularization during tissue regeneration 32 . However, incomplete decellularization, mechanical fragility, challenges in sterilization, and difficulties in large-scale production remain major drawbacks that limit their standardized clinical use 33 . Current research is therefore focused on addressing these limitations, particularly by optimizing decellularization protocols and improving the mechanical stability of the resulting scaffolds
Martínez-López et al. evaluated the biological characteristics of decellularized porcine oviduct ECM obtained through the immersion–agitation method 34 . This native-tissue-derived scaffold was assessed in the context of potential repair of reproductive organs. Outcomes revealed that the chosen decellularization protocol achieved satisfactory results, and crucial components of ECM, which in the case of uterine tubes are collagen I and III, proteoglycans, laminin, glycoprotein, and elastic fibers, were preserved. A novel approach was studied by testing the scaffold’s biocompatibility and biotoxicity by co-cultivation with spermatozoa. Results showed that sperm viability and motility were maintained, thus confirming the safety of the decellularization process, as well as the favorable biological response of the oviduct-based scaffold. Decellularization protocols were also assessed by Sanguansook et al. in order to harvest a natural collagen-based scaffold derived from organs of the female upper genital tract (animal model) 35 . Three different approaches, principally based on the number of decellularization cycle repetitions, were tested. The main decellularization agents were 0.1% sodium dodecyl sulfate and 1% Triton X-100 (protocols 1 and 2). The third protocol also included deoxyribonuclease. Conclusively, the outcomes revealed that incubation with deoxyribonuclease was the most efficient method for decellularization in terms of preserving DNA residues and ECM. However, in the case of oviducts, several components of the ECM were decreased. Authors also tested cytotoxicity by sperm-scaffold interaction and concluded that additional washing after the decellularization process is crucial in terms of enhancing safety and biocompatibility of the material. In a broader context, collagen scaffolds have also demonstrated promising regenerative capacity for reconstructing hollow organs, owing to their biocompatibility and structural resemblance to the native ECM 36 . Moreover, a crucial biomechanical characteristic, reversible radial expansion, has been observed. Maintaining this property is particularly important in the context of uterine tube tissue engineering, as it facilitates oocyte and embryo transport, which are contingent upon the peristaltic activity of the oviductal wall and the proper functioning of the cilia.
Besides collagen, several other natural polymers, including gelatin, chitosan, alginate, and hyaluronic acid, have been explored for applications in uterine and ovarian TERM 37 . These materials have been investigated as potential carriers for drugs, exosomes, or anti-inflammatory molecules 38 . For instance, gelatin/polycaprolactone (PCL) electrospun membranes have been evaluated in an animal model for the restoration of damaged endometrial structure and function. Histological analyses, gene expression of estrogen receptors and tumor necrosis factor (TNF), uterine morphology, and fertility outcomes were assessed. The results demonstrated successful regeneration of the endometrium, characterized by increased thickness, enhanced proliferation of epithelial and stromal cells, neovascularization, elevated expression of estrogen receptor α, and reduced TNF expression. The uterine cavity morphology was preserved, and comprehensive tissue regeneration resulted in improved fertility in female rats 39 . Another experimental study identified chitosan oligosaccharides as effective immunomodulators with a protective effect on ovarian tissue 40 . Similarly, alginate-based and hyaluronic acid–based hydrogels exhibited pronounced anti-inflammatory properties, particularly in the prevention of adhesion formation following surgical interventions41,42.
Restoration of fertility ultimately depends on the proper function of the reproductive organs as an integrated system. Therefore, research focused on other reproductive tissues can provide valuable insights applicable to the regeneration and functional recovery of damaged uterine tubes.
Synthetic biomaterials for uterine tubes regeneration
Scaffolds based on synthetic polymers are also widely utilized in TERM due to their high tunability, reproducibility, and mechanical strength 43 . Compared to natural polymers, synthetic materials, such as polylactic acid (PLA), polyglycolic acid (PGA), and PCL, offer precise control over biodegradation, porosity, and mechanical properties, making them well suited for applications that require structural integrity or long-term support 44 . In addition, their consistent quality and ease of large-scale production reduce batch-to-batch variability and facilitate regulatory approval processes 45 .
PLA is a thermoplastic aliphatic polyester derived from renewable resources such as corn starch or sugarcane 46 . Among its most notable characteristics are excellent biocompatibility, well-controlled biodegradability, and high mechanical stability 47 . PLA has been extensively employed as a scaffolding material for both hard- and soft-tissue engineering applications 48 . However, its inherent hydrophobicity remains a major limitation, as it negatively affects cellular attachment and overall biological performance. To address this drawback, surface modification of PLA scaffolds or blending with natural and other synthetic polymers is commonly utilized to enhance hydrophilicity and bioactivity 49 . PGA is a biodegradable aliphatic polyester well known for its good biocompatibility 50 . It has been successfully used in clinical practice, particularly in resorbable sutures, and represents a promising candidate for applications in skin and neural tissue engineering51,52. Due to its hydrolytic instability, which leads to a relatively fast degradation rate, PGA is frequently copolymerized with PLA to improve its mechanical properties and to achieve a more controlled degradation profile 53 . PCL is a semi-crystalline, biodegradable polyester characterized by high flexibility, slow degradation rate, and excellent processability 54 . These properties make PCL particularly suitable for use in additive manufacturing techniques, including 3D printing and bioprinting, thus enabling its application across a wide range of TERM fields 55 .
Synthetic scaffolds often lack inherent bioactivity and often require surface modification or the incorporation of bioactive molecules to support efficient cellular response. Furthermore, some synthetic polymers can produce acidic degradation byproducts that may induce in situ inflammation 56 . In contrast to natural scaffolds, which more closely mimic the ECM, synthetic materials may exhibit lower biocompatibility without additional functionalization 57 . A modified 3D biodegradable poly(lactic-co-glycolic acid) (PLGA) scaffold was evaluated for its potential to recanalize damaged uterine tubes 58 . Apelin-13-loaded microspheres were incorporated as a bioactive modifier to enhance the recanalization process in a chronic oviductal inflammation animal model. Four weeks after implantation, the best anatomical and functional restoration was observed in the group treated with Apelin-13-loaded scaffolds. These findings underscore the superior efficacy of using scaffolds as delivery vehicles for bioactive agents compared to the direct application of microspheres alone.
According to our knowledge, it appears that there are currently very few peer-reviewed studies specifically detailing the application of synthetic polymer scaffolds in uterine tubes. However, certain synthetic polymers such as PCL, PLA, and PGA have been extensively utilized in the engineering of other reproductive tissues, notably the uterus and vagina. For instance, a study by Hanuman et al. developed a PCL-based scaffold for uterine tissue engineering, demonstrating favorable mechanical properties and biocompatibility 59 . Similarly, porous poly-l-lactide-co-ɛ-caprolactone (PLCL) scaffolds have been employed in vaginal tissue regeneration, offering controlled degradation rates and structural support conducive to tissue remodeling60,61. In addition, the chemical modification of a PCL nanofibrous scaffold for uterine regeneration was also evaluated. In this study, the scaffold surface was functionalized with maltose and subsequently analyzed for its biological behavior and mechanical properties. The results demonstrated that the modified structure provided a favorable environment for the attachment and proliferation of human uterine fibroblasts. Overall, the maltose-conjugated electrospun PCL scaffold exhibited suitable characteristics for potential application in uterine tissue engineering 62 . These findings may also prove beneficial and transferable to the field of uterine tube tissue engineering within the scope of TERM.
Hydrogels for uterine tubes regeneration
Hydrogels are defined as three-dimensional (3D) hydrophilic polymeric networks with the enhanced ability to absorb and retain large amounts of water while maintaining structural integrity 63 . Their application in TERM is attractive due to their excellent biomimetic properties, biocompatibility, and also biodegradability 64 . Moreover, properties such as moldability and injectability enable their use in additive manufacturing technologies, making them promising candidates for personalized medicine 65 . The connection between hydrogels and their application in uterine tube tissue engineering lies in their ability to recapitulate the physicochemical and biological properties of the native ECM 66 . Their highwater content, tunable mechanical properties, and biocompatibility create a favorable microenvironment that supports cellular adhesion, proliferation, and differentiation of both epithelial and smooth muscle cells, which are the key components of uterine tube histology 67 . Moreover, the injectability and moldability of hydrogels facilitate minimally invasive delivery and enable the fabrication of complex, tubular scaffold structures that mimic the anatomical and functional features of the oviduct 68 . Hydrogels can also be functionalized to incorporate bioactive molecules such as growth factors, cytokines, or stem cells, thereby enhancing tissue regeneration and functional restoration 69 . These characteristics position hydrogels as highly suitable scaffolding materials for the reconstruction and repair of uterine tubes following injury, disease, or sterilization procedures.
Ribes Martinez et al. 70 evaluated a bovine decellularized ECM (dECM)-based hydrogel as a bio-ink for oviductal bioprinting. To assess cytocompatibility, oviductal cells were encapsulated within the hydrogel, and cell viability and proliferation were monitored over a 2-week culture period. The results demonstrated that the addition of alginate was crucial for achieving the desired mechanical properties. The engineered ECM-derived hydrogel exhibited suitable biocompatibility, favorable biomechanical characteristics, and effective support for cellular responses. Although a relatively low porosity was observed, the overall findings suggest that this hydrogel-based scaffold holds significant promise for advancing uterine tube tissue engineering. Increasing the porosity of hydrogel-based scaffolds improves their biomimetic properties, as well as the diffusion of nutrients and oxygen transport to cells located within the inner layers of the construct. Another critical factor is the control of hydrogel degradation mediated by the seeded cells. For instance, the addition of 1% alginate has been shown to enhance the structural stability of cell-seeded hydrogels. However, this modification often compromises cell viability. Therefore, identifying the optimal ratio of polymeric components is essential to maintain a balance between mechanical stability and biological performance.
Oviductal dECM was utilized for in vitro oocyte maturation as well as embryo culture 71 . Hydrogel derived from oviductal dECM depicted good biocompatibility with embryo development. In addition, microvascularization was promoted as well. Given that fertilization takes place in the uterine tubes and that their microenvironment provides critical support for early embryonic development, regenerative medicine has shown growing interest in investigating and developing tissue-derived hydrogels from this anatomical site.
In vitro embryo culture often fails to replicate the complex physiological environment of the reproductive tract, leading to developmental variations in mammalian embryos. A study conducted by Francés-Herrero et al. explored oviductal ECM-based hydrogel (OviECM), derived from decellularized rabbit oviducts, as a biologically relevant material to improve in vitro culture conditions 72 . The OviECM hydrogels were applied as culture coatings for two-cell embryos and compared to standard in vitro conditions. While no morphological differences were observed, embryos cultured with OviECM showed upregulated gene expression in immune and cellular response pathways. In addition, the OviECM group demonstrated higher implantation and live birth rates, as well as increased postnatal body weights over 20 weeks. These findings suggest that OviECM hydrogel coatings enhance embryo development and reduce postnatal phenotypic deviations, therefore offering a promising strategy to improve the safety and efficacy of assisted reproductive technologies.
To study the morphological and physiological properties of the uterine tubes, free-floating collagen-based hydrogels were utilized 73 . Together with bovine oviductal epithelial cells, tissue-mimicking in vitro models were generated and allowed to examine intercellular junctions, cellular ultrastructure, and OVGP1 gene expression, which plays a crucial role in fertilization and early development of the embryo. The tissue model demonstrated similar characteristics to native oviductal tissue and also showed potential for studying both oviductal physiology and pathology. Obtained knowledge could contribute to a better understanding of the factors influencing the success or failure of fertilization within the microenvironment of the uterine tubes.
A thermosensitive hydrogel combined with mesenchymal stem cells (MSCs) was evaluated for its potential to repair the uterine tube wall in an animal model 74 . The stem cells, isolated from dental pulp tissue, were incorporated into a PF127 hydrogel matrix. Cellular characterization confirmed that these dental pulp stem cells possessed MSC-like features, including notable immunomodulatory and pro-angiogenic properties. The hydrogel exhibited excellent cytocompatibility, and when enriched with stem cells, it significantly enhanced uterine tube repair and regeneration by modulating the inflammatory response, promoting angiogenesis, and restoring epithelial function.
The summarized results concerning reviewed polymers in the context of uterine tube tissue engineering, including their benefits, drawbacks, and applications, are detailed in the accompanying table (Table 1). Despite promising advancements, challenges such as mechanical stability, immune response, and functional integration remain. Therefore, there is significant potential and necessity for further research to optimize these materials and develop novel hybrid approaches that better mimic the complex microenvironment of the uterine tubes, ultimately improving clinical outcomes.
Table 1.
Summarization of the advantages, disadvantages, and applications of natural polymers, synthetic polymers, and hydrogels utilized in uterine tube tissue engineering.
| Polymer type | Examples | Advantages | Disadvantages | Applications | References |
|---|---|---|---|---|---|
| Natural polymers | • Collagen • dECM (porcine, rabbit oviduct) |
• Excellent biocompatibility • Bioactivity & biodegradability • Mimic native ECM • Support cell adhesion & differentiation • Reversible radial expansion |
• Poor mechanical strength • Rapid degradation • Difficult to modify properties • Possible immunogenic contaminants |
• In vitro culture of oviductal and ute cells • Uterine tube regeneration • Sperm–scaffold interaction tests • Hollow organ reconstruction |
Venkataraman et al. 30 , Martínez-López et al. 34 , Sanguansook et al. 35 , Versteegden et al. 36 |
| Synthetic polymers | • PLGA | • Tunable mechanical and degradation properties • High reproducibility • Structural integrity • Easy to manufacture • Good for bioactive agent delivery |
• Lack of inherent bioactivity • Risk of acidic degradation byproducts • Requires modification for biocompatibility |
• Recanalization of damaged uterine tubes | Zhao et al. 58 |
| Hydrogels | • Oviduct-derived ECM hydrogel • Alginate-enhanced ECM • PF127 + MSCs • OviECM (rabbit oviduct) |
• High water content • Injectable, moldable • Mimic ECM • Support angiogenesis & cell growth • Can carry bioactive agents or stem cells |
• Often low porosity • Mechanical strength limitations • May require additives (e.g., alginate) |
• Oviduct bioprinting • In vitro embryo/oocyte culture • Enhance implantation/live birth rates • Repair of damaged uterine tubes (animal models) |
Ribes Martinez et al. 70 , Francés-Herrero et al.71,72, Peña-Zanoni et al. 73 , Luo et al. 74 |
dECM: decellularized ECM; ECM: extracellular matrix; OviECM: oviductal ECM; MSCs: mesenchymal stem cells; PLGA: poly(lactic-co-glycolic acid).
Organoids
Nowadays, uterine tube organoids are considered to be one of the best 3D systems providing crucial experimental models for investigating various pathologies, including high-grade serous ovarian cancer. Organoids can be derived from adult stem cells (ASCs) or induced pluripotent stem cells (iPSCs). IPSC-derived organoids have the capacity to differentiate into various cell types of the three germ disk layers (endoderm, mesoderm, ectoderm), thanks to their pluripotency. Therefore, iPSC-derived organoids are more favorable than organoids derived from ASCs 75 . Generally, the generation of organoids starts with the target differentiation of ASCs/iPSCs into specific cell lines, and subsequently, the cell culture is supplemented with specific growth and signaling factors that modulate wingless-related integration site (Wnt), Notch, tumor growth factor beta (TGF-β), epidermal growth factor (EGF), and fibroblast growth factor (FGF) signaling pathways. Under these conditions, pluripotent stem cells undergo a process similar to organogenesis in a dish, enabling them to form 3D organ-like structures 76 . Without a doubt, the key to successful organoid formation is the proper combination of the mentioned factors within the expansion medium (Fig. 2). Organoids derived from tissue-derived cells are composed mainly of epithelial tissue cells. In the case of the uterine tube, the dominant part of the organoid is made up of epithelial secretory cells and ciliated cells. Among the first models was the “ex vivo” transwell-based air-liquid interference culture derived from primary human uterine tube epithelium 77 . The authors constructed this model to study carcinogenic factors of ovarian cancer. Based on their results, the ex vivo construct recapitulated the histology and functionality of the human uterine tube epithelium. Moreover, the system responded to genotoxic stress by secretion of biomarkers typical for ovarian cancer. The disadvantage of the mentioned construct is that uterine tube epithelial cells cannot be propagated in long term. This issue was later resolved by Kessler et al. 78 , who incorporated the regulation of Notch and Wnt pathways into the organoid-generation process. The authors generated uterine tube organoids from ASCs (EpCAM+) isolated from the human uterine tube epithelium (epithelial stem cells). The crucial part of the organoid differentiation involved culture supplementation with a cocktail of growth factors that regulate the Notch and Wnt, EFG, FGF-10, and TGF-β signaling pathways, including human noggin, nicotinamide, a ROCK inhibitor (Y-27632), and SB431542. Thanks to the regulation of the abovementioned signaling pathways, the 3D-generated uterine tube organoids containing ciliated and secretory epithelial cells displayed decreased proliferation and an increased number of ciliated cells, thus faithfully recapitulating the mucosal fold architecture.
Another research group generated uterine tube organoids from the epithelial layer of the human uterine tube 79 . The samples were obtained after salpingectomy from the fimbria of the oviduct. The first step of epithelial cell processing involved their cultivation on pre-coated six-well dishes with Matrigel. After 14 days, colony formation was observed. Subsequently, the large cellular spheres were differentiated into organoid cultures, which were cultivated in a specific medium containing the aforementioned factors, including EGF, FGF-10, noggin, Wnt3a, along with the addition of nicotinamide, Y-27632, and RSPO1. As an ECM, Matrigel was used again. The organoid was cultivated in conjunction with MSCs isolated from uterine tube stroma and human umbilical vein endothelial cells (HUVEC). The primary population of human epithelial cells from the uterine tube was also used by Dai et al. 80 to establish the uterine tube organoid. These organoids served as a model of a particular malignancy carrying mutations TP53 and RAD51D, which are typical for an early stage of high-grade serous ovarian cancer. Such an organoid exhibited higher cell proliferation and an elevated IL-17 signaling pathway, typical of tumor progression, making it an applicable in vitro construct for detecting early carcinomas and potential drug screening.
As mentioned earlier, iPSC-derived organoids possess better differentiation potential than ASCs. The research group of Yucer et al. 81 generated iPSCs from healthy individuals and patients with epithelial ovarian cancer carrying pathogenic BRCA1 mutations (BRCA1 mut ). Following the differentiation of pathologic iPSC lines into uterine tube organoids, cellular abnormalities characteristic of the neoplastic transformation process were observed, including increased secretion of cancer-specific proteins. According to the results, the cells of the control uterine tube organoids reached complete maturation, including TUBB4A+ ciliated cells and PAX8+ secretory cells. In contrast, cells of BRCA1 mut organoids displayed a loss of identity and apical-to-basal polarity, as well as a varied distribution of tissue thickness after 4 months of cultivation. All the mentioned characteristics of BRCA1 mut uterine tube organoids recapitulate features similar to serous tubal intraepithelial carcinoma, proving that 3D cellular constructs represent a suitable physiological tool enabling deeper study of pathological events occurring during the initial stages of the cancer process.
Another essential part of this process is the ECM, in which stem cells are embedded. Among the most used ECMs are the commercially available Matrigel or Geltrex, which can mimic a specific tissue microenvironment 82 .
However, the widely used Matrigel poses a significant challenge for the long-term cultivation of organoids due to its instability and insufficient content, which lacks many ECM features of the uterine tube microenvironment. Therefore, sooner or later, the Matrigel as ECM for organoid formation will need to be replaced by a more suitable alternative, such as a porous collagen scaffold, artificial hydrogels, or engineered polyethylene glycol (PEG) hydrogels, which have been used in endometrial organoids83,84.
Similarly, uterine tube organoids serve as an in vitro model for drug screening and testing new therapeutic agents, thanks to the aforementioned features.
Three-dimensional bioprinting possibilities
Unlike organoids, 3D bioprinting offers a more precise way to organize different cell types within a biomaterial layer by layer, forming a complex structure with a microarchitecture resembling the native one. Among the first researchers to develop a 3D-printed technique combined with microfluidics to create a uterine tube model was Ferraz et al. 85 . The authors printed a U-shaped, 3D tubular-like insert using a multi-arm acrylate-based resin on a stereolithographer, enabling independent double perfusion while maintaining tubular morphology. The seeded bovine epithelial uterine tube cells were cultured in an air-liquid interference, which helped them to acquire and maintain apical and basolateral polarization for at least 6 weeks. However, further studies are necessary to investigate the ability of this construct to serve as a proper 3D uterine tube model. Most recently, Fontes et al. developed an in vitro 3D oviductal model using a magnetic bioprinting system 86 . The 3D system, called the oviductal magnetic spheroid, was formed by magnetizing bovine tubal epithelial and stromal cells with nanoparticles placed in a magnetic field. These spheroids self-organized and recapitulated uterine tube features, including the presence of ciliated epithelial cells facing outwards, expression of a secretory marker, and epithelial support provided by stromal cells, within 7 days of cultivation. However, the authors noted several limitations of this 3D system, such as potential cell dedifferentiation, a time-consuming protocol, and a weak spheroid response to estrogen treatment.
Generally, forming a 3D bioengineered uterine tube model is challenging due to the organ’s complexity, including its epithelial, mucosal, and muscular layers, as well as regional differences (fimbriae, ampulla, isthmus). At the histological level, achieving ciliary beating and coordinated muscular contraction is also very challenging. Last but not least, the tissue constructs of this size require a functional blood supply, which remains a significant obstacle to be addressed in future research.
Future directions
Despite extensive research and discourse on female infertility, the uterine tube remains a relatively understudied structure within the domains of TERM. On the other hand, current research on biomaterials is rapidly advancing, offering smart materials with the ability to regulate and directly influence pathological processes in affected tissues 87 . For these reasons, advanced biomaterials might provide an effective tool for oviductal regeneration and reconstruction. Current technologies enable the engineering of biomimetic hydrogels with the capacity to mimic the native oviduct’s ECM, thereby supporting epithelial cell differentiation, cilia formation, and secretory function88–90. The Oviduct-on-a-Chip approach facilitates the study of highly delicate processes, such as fertilization, gamete transport, or embryo-maternal crosstalk. In addition, a study conducted by Ferraz et al. introduces this approach as an accurate platform that better mimics the in vivo environment of early embryonic development compared to conventional IVF, preventing poly-spermic fertilization and supporting improved epigenetic reprogramming and embryo quality91,92. Moreover, reduced concentrations of reactive oxygen species can also be obtained 93 .
Both natural and synthetic scaffolds can be modified by various bioactive agents, which can positively affect the restoration of damaged tissue 94 . In the context of tubal factor infertility, materials capable of regulating and healing inflammation processes seem very promising. According to recent studies, the leading cause of tubal factor infertility is blockage of the uterine tubes, most often resulting from sexually transmitted infections such as Chlamydia trachomatis or Neisseria gonorrhoeae 95 . They cause severe inflammation—salpingitis. However, several other conditions can impair tubal patency as well. These include pelvic infections like adhesions caused by abdominal tuberculosis, damage from previous tubal surgeries or sterilization procedures, ischemic nodules, endometriosis, the presence of polyps or mucus, tubal spasms, and congenital abnormalities of the tubes96,97. In addition, peritoneal factors such as peritubal adhesions, endometriosis, impaired tubal motility, and blockage at the fimbrial end can also negatively affect the function and openness of the uterine tubes 98 . Based on the etiology of oviduct damage, materials with the potential to support their regeneration should be designed to reduce and treat inflammation, promote tissue vascularization, and positively influence the natural immunological processes occurring within the uterine tubes 99 . Effective resolution of bacterial infections is crucial, as untreated cases can progress to chronic inflammatory states, leading to oviductal obstruction and subsequent infertility. Chitosan-based scaffolds have been proposed as an efficient delivery system for localized tissue healing in numerous studies dealing with the female genital tract100–102. For the in situ treatment of sexually transmitted disease-affected oviducts (mainly Chlamydia trachomatis and Neisseria gonorrhoeae), polymeric delivery systems loaded with tetracycline- and cephalosporin-based antibiotics offer a promising and targeted therapeutic strategy, enabling localized and sustained antimicrobial activity103,104.
Polymer-based scaffolds have also been studied as devices for permanent female sterilization 105 . On the other hand, loading with accurate bioactive agents, such as anti-inflammatory molecules, hormones, growth factors, antioxidants, enzymes, and matrix modulators, could enhance the function of the female reproductive tract. However, the current status of research in this area is lacking.
The integration of artificial intelligence (AI) into scaffold engineering procedures may also present a significant future direction in oviductal regeneration. This approach could improve crucial properties needed for successful in vivo implantation, such as material selection, personalized design, and enhanced biological responsiveness 106 . By overall improving scaffold performance, AI-driven scaffold engineering holds the potential for quicker clinical translation, enhanced patient outcomes, and lower production costs. On the other hand, the remaining challenges include obtaining relevant data, overcoming regulatory issues, and achieving smooth and optimized integration with common biomedical workflows 107 .
Conclusion
Biomaterial-based strategies offer a promising approach for restoring the structure and function of the uterine tubes, addressing one of the major causes of female infertility. Natural and synthetic polymers, hydrogels, and organoid systems have demonstrated encouraging results in mimicking the native oviductal environment and supporting epithelial differentiation, angiogenesis, and regeneration. However, achieving full functional restoration remains a challenge. Continued interdisciplinary research integrating advanced biomaterials, stem cell technologies, and bioprinting approaches will be essential to translate these experimental findings into clinically viable therapies that can ultimately enhance fertility outcomes.
Footnotes
ORCID iD: Martina Culenova
https://orcid.org/0009-0005-3484-0002
Ethical Considerations: Not applicable.
Author Contributions: M.C. designed the review structure and conducted the literature review regarding natural and synthetic polymers as well as hydrogels. M.K. performed a literature search concerning the anatomy and histology of the uterine tube and organoids derived from the uterine tubes. M.K. prepared original figures. Both authors contributed to the result analysis, article writing revising, and finalization of the manuscript.
Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the EU NextGenerationEU through the Recovery and Resilience Plan for Slovakia under the project No. 09I0X-03-V04-00290.
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Data Availability Statement: The references used for the writing of this manuscript are publicly available.
Statement of Human and Animal Rights: This article does not contain any studies with human or animal subjects.
Statement of Informed Consent: Not applicable.
References
- 1. Ramírez-González J, Vaamonde-Lemos R, Cunha-Filho J, Varghese A, Swanson R. Overview of the female reproductive system. In: Vaamonde D, du Plessis S, Agarwal A, editors. Exercise and Human reproduction. New York: Springer. Doi: 10.1007/978-1-4939-3402-7_2. [DOI] [Google Scholar]
- 2. Yan J, Wu T, Zhang J, Gao Y, Wu JM, Wang S. Revolutionizing the female reproductive system research using microfluidic chip platform. J Nanobiotechnology. 2023;21(1):490. doi: 10.1186/s12951-023-02258-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Stejskalová A, Vankelecom H, Sourouni M, Ho MY, Götte M, Almquist BD. In vitro modelling of the physiological and diseased female reproductive system. Acta Biomater. 2021;132:288–312. doi: 10.1016/j.actbio.2021.04.032. [DOI] [PubMed] [Google Scholar]
- 4. Jia X, Rana N, Crouss T, Whitmore KE. Gynecological associated disorders and management. Int J Urol. 2019;26(Suppl1):46–51. doi: 10.1111/iju.13974. [DOI] [PubMed] [Google Scholar]
- 5. Li S, Winuthayanon W. Oviduct: roles in fertilization and early embryo development. J Endocrinol. 2017;232(1):R1–R26. doi: 10.1530/JOE-16-0302. [DOI] [PubMed] [Google Scholar]
- 6. Yamamoto Y, Kurokawa M, Ogawa T, Kubota S, Kimura K. Involvement of gap junctions in the increased contraction of bovine oviducts at pre-ovulation observed in vitro. Reproduction. 2023;165(3):301–12. doi: 10.1530/REP-22-0174. [DOI] [PubMed] [Google Scholar]
- 7. Owhor LE, Reese S, Kölle S. Salpingitis impairs bovine tubal function and sperm-oviduct interaction. Sci Rep. 2019;9:10893. doi: 10.1038/s41598-019-47431-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Carson SA, Kallen AN. Diagnosis and management of infertility: a review. JAMA. 2021;326(1):65–76. doi: 10.1001/jama.2021.4788. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Lindsay TJ, Vitrikas KR. Evaluation and treatment of infertility [published correction appears in Am Fam Physician. 2015;92(6):437]. Am Fam Physician. 2015;91(5):308–14. [PubMed] [Google Scholar]
- 10. Jain M, Singh M. Assisted Reproductive Technology (ART) Techniques. Treasure Island (FL): StatPearls Publishing; 2025. https://www.ncbi.nlm.nih.gov/books/NBK576409/ [accessed 2023 Jun 7] [PubMed] [Google Scholar]
- 11. Bing Y, Ouellette RJ. Fertilization in vitro. Methods Mol Biol. 2009;550:251–66. doi: 10.1007/978-1-60327-009-0_16. [DOI] [PubMed] [Google Scholar]
- 12. Phillips K, Olanrewaju RA, Omole F. Infertility: evaluation and management. Am Fam Physician. 2023;107(6):623–30. [PubMed] [Google Scholar]
- 13. Shingshetty L, Cameron NJ, Mclernon DJ, Bhattacharya S. Predictors of success after in vitro fertilization. Fertil Steril. 2024;121(5):742–51. doi: 10.1016/j.fertnstert.2024.03.003. [DOI] [PubMed] [Google Scholar]
- 14. Zafarani F, Ghaffari F, Ahmadi F, Soleimani Mehranjani M, Shahrzad G. Hysterosalpingography in the assessment of proximal tubal pathology: a review of congenital and acquired abnormalities. Br J Radiol. 2021;94(1122):20201386. doi: 10.1259/bjr.20201386. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Adhikari B, Stager MA, Krebs MD. Cell-instructive biomaterials in tissue engineering and regenerative medicine. J Biomed Mater Res A. 2023;111(5):660–81. doi: 10.1002/jbm.a.37510. [DOI] [PubMed] [Google Scholar]
- 16. Xue Z, Li J, Feng J, Han H, Zhao J, Zhang J, Han Y, Wu X, Zhang Y. Research progress on the mechanism between polycystic ovary syndrome and abnormal endometrium. Front Physiol. 2021;12:788772. doi: 10.3389/fphys.2021.788772. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Văduva C-C, Dîră L, Boldeanu L, Șerbănescu M-S, Carp- Velișcu A. A narrative review regarding implication of ovarian endometriomas in infertility. Life. 2025;15(2):161. doi: 10.3390/life15020161. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Kim SY, Kim SK, Lee JR, Woodruff TK. Ovary is necessary to the health of uterus. J Gynecol Oncol. 2016;27(3):e35. doi: 10.3802/jgo.2016.27.e35. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Hanuman S, Pande G, Nune M. Current status and challenges in uterine myometrial tissue engineering. Bioengineered. 2023;14(1):2251847. doi: 10.1080/21655979.2023.2251847 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Han J, Sadiq NM. Anatomy, abdomen and pelvis: uterine tube. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK547660/ [Updated 2023 Jul 24]. [Google Scholar]
- 21. Howard C, Rice PFS, Keenan M, et al. Study of uterine tube anatomy and mechanical properties to determine pressure limits for endoscopic exploration. J Histotechnol. 2022;45(1):10–20. doi: 10.1080/01478885.2021.1972250. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Caillol S. Special issue “Natural polymers and biopolymers II..” Molecules. 2020;26(1):112. doi: 10.3390/molecules26010112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Satchanska G, Davidova S, Petrov PD. Natural and synthetic polymers for biomedical and environmental applications. Polymers. 2024;16(8):1159. doi: 10.3390/polym16081159. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Paradowska-Stolarz A, Wieckiewicz M, Owczarek A, Wezgowiec J. Natural polymers for the maintenance of oral health: review of recent advances and perspectives. Int J Mol Sci. 2021;22(19):10337. doi: 10.3390/ijms221910337. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Aamodt JM, Grainger DW. Extracellular matrix-based biomaterial scaffolds and the host response. Biomaterials. 2016;86:68–82. doi: 10.1016/j.biomaterials.2016.02.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Dong C, Lv Y. Application of collagen scaffold in tissue engineering: recent advances and new perspectives. Polymers. 2016;8(2):42. doi: 10.3390/polym8020042. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. He Q, Feng T, Xie Y, Swamiappan S, Zhou Y, Zhou Y, Zhou H, Peng X. Recent advances in the development and application of cell-loaded collagen scaffolds. Int J Mol Sci. 2025;26(9):4009. doi: 10.3390/ijms26094009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Ferreira AM, Gentile P, Chiono V, Ciardelli G. Collagen for bone tissue regeneration. Acta Biomater. 2012;8(9):3191–200. doi: 10.1016/j.actbio.2012.06.014. [DOI] [PubMed] [Google Scholar]
- 29. Kaczmarek-Szczepańska B, Polkowska I, Małek M, et al. The characterization of collagen-based scaffolds modified with phenolic acids for tissue engineering application. Sci Rep. 2023;13:9966. doi: 10.1038/s41598-023-37161-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Venkataraman L, Upadhyay S, Lalitkumar PG, Sengupta J, Ghosh D. Morphological and functional characteristics of rabbit uterine epithelial cells grown on free floating collagen gel. Indian J Physiol Pharmacol. 2001;45(2):161–71. [PubMed] [Google Scholar]
- 31. Yu Y, Alkhawaji A, Ding Y, Mei J. Decellularized scaffolds in regenerative medicine. Oncotarget. 2016;7(36):58671–83. doi: 10.18632/oncotarget.10945. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Zhang X, Chen X, Hong H, Hu R, Liu J, Liu C. Decellularized extracellular matrix scaffolds: recent trends and emerging strategies in tissue engineering. Bioact Mater. 2021;10:15–31. doi: 10.1016/j.bioactmat.2021.09.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. García-Gareta E, Abduldaiem Y, Sawadkar P, Kyriakidis C, Lali F, Greco KV. Decellularised scaffolds: just a framework? Current knowledge and future directions. J Tissue Eng. 2020;11:2041731420942903. doi: 10.1177/2041731420942903. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Martínez-López C, Martínez-Cáceres CM, Cortina-Navarro M, Izquierdo-Rico MJ, García-Vázquez FA. Characterization of decellularized porcine oviduct- and uterine-derived scaffolds evaluated by spermatozoa-based biocompatibility and biotoxicity. Theriogenology. 2025;231:36–51. doi: 10.1016/j.theriogenology.2024.10.005. [DOI] [PubMed] [Google Scholar]
- 35. Sanguansook P, Martínez-López C, Izquierdo-Rico MJ, Martínez-Cáceres C, López-Orozco M, Chatdarong K, García-Vázquez FA. Development of decellularization protocols for female cat reproductive organs. Res Vet Sci. 2024;173:105257. doi: 10.1016/j.rvsc.2024.105257. [DOI] [PubMed] [Google Scholar]
- 36. Versteegden LR, van Kampen KA, Janke HP, et al. Tubular collagen scaffolds with radial elasticity for hollow organ regeneration. Acta Biomater. 2017;52:1–8. doi: 10.1016/j.actbio.2017.02.005 [DOI] [PubMed] [Google Scholar]
- 37. Sun W, Xu W, Xiao M, et al. Enhancing exosome stability and delivery with natural polymers to prevent intrauterine adhesions and promote endometrial regeneration: a review. J Nanobiotechnology. 2025;23(1):529. doi: 10.1186/s12951-025-03603-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Li X, Lv HF, Zhao R, Ying MF, Samuriwo AT, Zhao YZ. Recent developments in bio-scaffold materials as delivery strategies for therapeutics for endometrium regeneration. Mater Today Bio. 2021;11:100101. doi:10.1016/j.mtbio.2021.100101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Wang X, Yang CR, Zhao ZD, Liu DG, Li CZ. Gelatin/polycaprolactone membranes promote endometrial regeneration and restore fertility. Gynecol Endocrinol. 2024;40(1):2442728. doi: 10.1080/09513590.2024.2442728. [DOI] [PubMed] [Google Scholar]
- 40. Li X, Ye H, Su T, Hu C, Huang Y, Fu X, Zhong Z, Du X, Zheng Y. Immunity and reproduction protective effects of Chitosan Oligosaccharides in Cyclophosphamide/Busulfan-induced premature ovarian failure model mice. Front Immunol. 2023;14:1185921. doi: 10.3389/fimmu.2023.1185921. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Zhou Q, Shi X, Saravelos S, Huang X, Zhao Y, Huang R, Xia E, Li TC. Auto-cross-linked hyaluronic acid gel for prevention of intrauterine adhesions after hysteroscopic adhesiolysis: a randomized controlled trial. J Minim Invasive Gynecol. 2021;28(2):307–13. doi: 10.1016/j.jmig.2020.06.030. [DOI] [PubMed] [Google Scholar]
- 42. Liang Y, Shuai Q, Zhang X, Jin S, Guo Y, Yu Z, Xu X, Ao R, Peng Z, Lv H, He S, et al. Incorporation of decidual stromal cells derived exosomes in sodium alginate hydrogel as an innovative therapeutic strategy for advancing endometrial regeneration and reinstating fertility. Adv Healthc Mater. 2024;13(13):e2303674. doi: 10.1002/adhm.202303674. [DOI] [PubMed] [Google Scholar]
- 43. Place ES, George JH, Williams CK, Stevens MM. Synthetic polymer scaffolds for tissue engineering. Chem Soc Rev. 2009;38(4):1139–51. doi: 10.1039/b811392k. [DOI] [PubMed] [Google Scholar]
- 44. Wu DT, Munguia-Lopez JG, Cho YW, et al. Polymeric scaffolds for dental, oral, and craniofacial regenerative medicine. Molecules. 2021;26(22):7043. doi: 10.3390/molecules26227043. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Ye B, Wu B, Su Y, Sun T, Guo X. Recent advances in the application of natural and synthetic polymer-based scaffolds in musculoskeletal regeneration. Polymers. 2022;14(21):4566. doi: 10.3390/polym14214566. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. de Albuquerque TL, Marques Júnior JE, de Queiroz LP, Ricardo ADS, Rocha MVP. Polylactic acid production from biotechnological routes: a review. Int J Biol Macromol. 2021;186:933–51. doi: 10.1016/j.ijbiomac.2021.07.074. [DOI] [PubMed] [Google Scholar]
- 47. Singhvi MS, Zinjarde SS, Gokhale DV. Polylactic acid: synthesis and biomedical applications. J Appl Microbiol. 2019;127(6):1612–26. doi: 10.1111/jam.14290. [DOI] [PubMed] [Google Scholar]
- 48. Lee JH, Park TG, Park HS, Lee DS, Lee YK, Yoon SC, Nam JD. Thermal and mechanical characteristics of poly(L-lactic acid) nanocomposite scaffold. Biomaterials. 2003;24(16):2773–78. doi: 10.1016/s0142-9612(03)00080-2. [DOI] [PubMed] [Google Scholar]
- 49. Ranakoti L, Gangil B, Mishra SK, et al. Critical review on polylactic acid: properties, structure, processing, biocomposites, and nanocomposites. Materials (Basel). 2022;15(12):4312. doi: 10.3390/ma15124312. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50. Samantaray PK, Little A, Haddleton DM, McNally T, Tan B, Sun Z, Huang W, Ji Y, Wan C. Poly(glycolic acid) (PGA): a versatile building block expanding high performance and sustainable bioplastic applications. Green Chem. 2020;22(13):4055–81. [Google Scholar]
- 51. Khiste SV, Ranganath V, Nichani AS. Evaluation of tensile strength of surgical synthetic absorbable suture materials: an in vitro study. J Periodontal Implant Sci. 2013;43(3):130–35. doi: 10.5051/jpis.2013.43.3.130. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52. Cai M, Han Y, Zheng X, et al. Synthesis of poly-γ-glutamic acid and its application in biomedical materials. Materials. 2023;17(1):15. doi: 10.3390/ma17010015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53. Yoon SK, Chung DJ. In Vivo degradation studies of PGA-PLA block copolymer and their histochemical analysis for spinal-fixing application. Polymers. 2022;14(16):3322. doi: 10.3390/polym1416332221. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Dwivedi R, Kumar S, Pandey R, Mahajan A, Nandana D, Katti DS, Mehrotra D. Polycaprolactone as biomaterial for bone scaffolds: review of literature. J Oral Biol Craniofac Res. 2020;10(1):381–88. doi: 10.1016/j.jobcr.2019.10.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55. Mousavi Nejad Z, Zamanian A, Saeidifar M, Vanaei HR, Salar Amoli M. 3D bioprinting of polycaprolactone-based scaffolds for pulp-dentin regeneration: investigation of physicochemical and biological behavior. Polymers. 2021;13(24):4442. doi: 10.3390/polym132444424. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56. Farjaminejad S, Farjaminejad R, Hasani M, et al. Advances and challenges in polymer-based scaffolds for bone tissue engineering: a path towards personalized regenerative medicine. Polymers. 2024;16(23):3303. doi: 10.3390/polym16233303. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Liu X, Holzwarth JM, Ma PX. Functionalized synthetic biodegradable polymer scaffolds for tissue engineering. Macromol Biosci. 2012;12(7):911–19. doi: 10.1002/mabi.201100466. [DOI] [PubMed] [Google Scholar]
- 58. Zhao Q, Xue M, Li Y, Zheng Y, Xu Z, Li Z. Preliminary study on a novel biological scaffold loaded with Apelin-13 sustained-release microcapsules for promoting uterine tube recanalization in rabbits. 载Apelin-13缓释微囊的新型生物支架促兔输卵管再通的初步研究. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023;48(9):1304–15. doi: 10.11817/j.issn.1672-7347.2023.230067. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59. Hanuman SBHK, Pai KSR, Nune M. Surface-conjugated galactose on electrospun polycaprolactone nanofibers: an innovative scaffold for uterine tissue engineering. ACS Omega. 2024;9(32):34314–28. doi: 10.1021/acsomega.3c10445 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60. Sartoneva R, Kuismanen K, Juntunen M, Karjalainen S, Hannula M, Kyllönen L, Hyttinen J, Huhtala H, Paakinaho K, Miettinen S. Porous poly-l-lactide-co-ɛ-caprolactone scaffold: a novel biomaterial for vaginal tissue engineering. R Soc Open Sci. 2018;5(8):180811. doi: 10.1098/rsos.180811. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61. Sartoneva R, Paakinaho K, Hannula M, Kuismanen K, Huhtala H, Hyttinen J, Miettinen S. Ascorbic acid 2-phosphate releasing supercritically foamed porous poly-L-lactide-Co-ε-caprolactone scaffold enhances the collagen production of human vaginal stromal cells: a new approach for vaginal tissue engineering. Tissue Eng Regen Med. 2024;21(1):81–96. doi: 10.1007/s13770-023-00603-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62. Hanuman S, Nune M. Design and characterization of maltose-conjugated polycaprolactone nanofibrous scaffolds for uterine tissue engineering. Regen. Eng. Transl. Med. 2022;8:334–44. doi: 10.1007/s40883-021-00231-0. [DOI] [Google Scholar]
- 63. Mathew AP, Uthaman S, Cho KH, Cho CS, Park IK. Injectable hydrogels for delivering biotherapeutic molecules. Int J Biol Macromol. 2018;110:17–29. doi: 10.1016/j.ijbiomac.2017.11.113. [DOI] [PubMed] [Google Scholar]
- 64. Slaughter BV, Khurshid SS, Fisher OZ, Khademhosseini A, Peppas NA. Hydrogels in regenerative medicine. Adv Mater. 2009;21(32–33):3307–29. doi: 10.1002/adma.200802106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65. Mancilla-De-la-Cruz J, Rodriguez-Salvador M, An J, Chua CK. Three-dimensional printing technologies for drug delivery applications: processes, materials, and effects. Int J Bioprint. 2022;8(4):622. doi: 10.18063/ijb.v8i4.622. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66. Gomez-Florit M, Pardo A, Domingues RMA, et al. Natural-based hydrogels for tissue engineering applications. Molecules. 2020;25(24):5858. doi: 10.3390/molecules25245858 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67. Parvin N, Kumar V, Joo SW, Mandal TK. Cutting-edge hydrogel technologies in tissue engineering and biosensing: an updated review. Materials. 2024;17(19):4792. doi: 10.3390/ma17194792 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68. Bertsch P, Diba M, Mooney DJ, Leeuwenburgh SCG. Self-healing injectable hydrogels for tissue regeneration. Chem Rev. 2023;123(2):834–73. doi: 10.1021/acs.chemrev.2c00179. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69. Wang X, Zeng J, Gan D, et al. Recent strategies and advances in hydrogel-based delivery platforms for bone regeneration. Nano-micro Lett. 2025;17:73. doi: 10.1007/s40820-024-01557-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70. Ribes Martinez E, Franko Y, Franko R, Ferronato GA, Viana AES, Windenbach E, Stoeckl JB, Fröhlich T, Ferraz MAMM. Developing and characterising bovine decellularized extracellular matrix hydrogels to biofabricate female reproductive tissues. Acta Biomater. 2025;196:152–70. doi: 10.1016/j.actbio.2025.03.009. [DOI] [PubMed] [Google Scholar]
- 71. Francés-Herrero E, De Miguel-Gómez L, López-Martínez S, Campo H, Garcia-Dominguez X, Diretto G, Faus A, Vicente JS, Marco-Jiménez F, Cervelló I. Development of decellularized oviductal hydrogels as a support for rabbit embryo culture. Reprod Sci. 2021;28(6):1644–58. doi: 10.1007/s43032-020-00446-6. [DOI] [PubMed] [Google Scholar]
- 72. Francés-Herrero E, Lorenzo-Rebenaque L, Casto-Rebollo C, et al. Oviductal extracellular matrix hydrogels enhance in vitro culture of rabbit embryos and reduce deficiencies during assisted reproductive technologies. Sci Rep. 2024;14(1):27579. doi: 10.1038/s41598-024-77583-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73. Peña-Zanoni M, García DC, Roldán-Olarte M, Valdecantos PA. A long-term in vitro culture of bovine epithelial cells on collagen rafts. Reprod Domest Anim. 2021;56(4):684–87. doi: 10.1111/rda.13896. [DOI] [PubMed] [Google Scholar]
- 74. Luo L, Zhu Q, Li Y, et al. Application of thermosensitive-hydrogel combined with dental pulp stem cells on the injured uterine tube mucosa in an animal model. Front Bioeng Biotechnol. 2023;10:1062646. doi: 10.3389/fbioe.2022.1062646. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75. Chumduri C, Turco MY. Organoids of the female reproductive tract. J Mol Med (Berl). 2021;99(4):531–53. doi: 10.1007/s00109-020-02028-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76. Yang J, Li W, Zhang Z, Xu Z, Zhu W, Wang J, Wang W. Development and applications of organoids in gynecological diseases. Stem Cell Rev Rep. 2025;21(3):629–44. doi: 10.1007/s12015-024-10833-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77. Levanon K, Ng V, Piao HY, Zhang Y, Chang MC, Roh MH, Kindelberger DW, Hirsch MS, Crum CP, Marto JA, Drapkin R. Primary ex vivo cultures of human uterine tube epithelium as a model for serous ovarian carcinogenesis. Oncogene. 2010;29(8):1103–13. doi: 10.1038/onc.2009.402. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78. Kessler M, Hoffmann K, Brinkmann V, Thieck O, Jackisch S, Toelle B, Berger H, Mollenkopf HJ, Mangler M, Sehouli J, Fotopoulou C, et al. The Notch and Wnt pathways regulate stemness and differentiation in human uterine tube organoids. Nat Commun. 2015;6:8989. doi: 10.1038/ncomms9989. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79. Chang YH, Chu TY, Ding DC. Human uterine tube epithelial cells exhibit stemness features, self-renewal capacity, and Wnt-related organoid formation. J Biomed Sci. 2020;27(1):32. doi: 10.1186/s12929-019-0602-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80. Dai Y, Xu J, Gong X, Wei J, Gao Y, Chai R, Lu C, Zhao B, Kang Y. Human uterine tube-derived organoids with TP53 and RAD51D mutations recapitulate an early stage high-grade serous ovarian cancer phenotype in vitro. Int J Mol Sci. 2024;25(2):886. doi: 10.3390/ijms25020886. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81. Yucer N, Ahdoot R, Workman MJ, Laperle AH, Recouvreux MS, Kurowski K, Naboulsi DJ, Liang V, Qu Y, Plummer JT, Gayther SA, et al. Human iPSC-derived uterine tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis. Cell Rep. 2021;37(13):110146. doi: 10.1016/j.celrep.2021.110146. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82. Cui Y, Zhao H, Wu S, Li X. Human female reproductive system organoids: applications in developmental biology, disease modelling, and drug discovery. Stem Cell Rev Rep. 2020;16(6):1173–84. doi: 10.1007/s12015-020-10039-0. [DOI] [PubMed] [Google Scholar]
- 83. Abbas Y, Brunel LG, Hollinshead MS, Fernando RC, Gardner L, Duncan I, Moffett A, Best S, Turco MY, Burton GJ, Cameron RE. Generation of a three-dimensional collagen scaffold-based model of the human endometrium. Interface Focus. 2020;10(2):20190079. doi: 10.1098/rsfs.2019.0079. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84. Gnecco JS, Brown A, Buttrey K, Ives C, Goods BA, Baugh L, Hernandez-Gordillo V, Loring M, Isaacson KB, Griffith LG. Organoid co-culture model of the human endometrium in a fully synthetic extracellular matrix enables the study of epithelial-stromal crosstalk. Med. 2023;4(8):554–5799. doi: 10.1016/j.medj.2023.07.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85. Ferraz MAMM, Henning HHW, Van Dorenmalen KMA, Vos PLAM, Stout TAE, Costa PF, Malda J, Gadella BM. 52 Use of transwell cell culture and 3-dimensional printing technology to develop an in vitro bovine oviduct. Reprod Fertil Dev. 2015;28:156–56. [Google Scholar]
- 86. Fontes PK, Silva ABFD, Bartoli ABDR, Antunes T, Júnior ARDS, Milazzotto MP. Three-dimensional magnetic bioprinting spheroids as an in vitro model to study the oviductal physiology. Mol Reprod Dev. 2025;92(8):e70049. doi: 10.1002/mrd.70049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87. Wei H, Cui J, Lin K, Xie J, Wang X. Recent advances in smart stimuli-responsive biomaterials for bone therapeutics and regeneration. Bone Res. 2022;10(1):17. doi: 10.1038/s41413-021-00180-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88. Lu P, Ruan D, Huang M, et al. Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions. Sig Transduct Target Ther. 2024;9:166. doi: 10.1038/s41392-024-01852-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89. Kang DH, Han WB, Il Ryu H, et al. Tunable and scalable fabrication of block copolymer-based 3D polymorphic artificial cell membrane array. Nat Commun. 2022;13:1261. doi: 10.1038/s41467-022-28960-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90. Kumar P, Ciftci S, Barthes J, Knopf-Marques H, Muller CB, Debry C, Vrana NE, Ghaemmaghami AM. A composite Gelatin/hyaluronic acid hydrogel as an ECM mimic for developing mesenchymal stem cell-derived epithelial tissue patches. J Tissue Eng Regen Med. 2020;14(1):45–57. doi: 10.1002/term.2962. [DOI] [PubMed] [Google Scholar]
- 91. Ferraz MAMM, Henning HHW, Costa PF, Malda J, Melchels FP, Wubbolts R, Stout TAE, Vos PLAM, Gadella BM. Improved bovine embryo production in an oviduct-on-a-chip system: prevention of polyspermic fertilization and parthenogenic activation. Lab Chip. 2017;17(5):905–16. doi: 10.1039/C6LC01566B. [DOI] [PubMed] [Google Scholar]
- 92. Ferraz MAMM, Rho HS, Hemerich D, Henning HHW, van Tol HTA, Hölker M, Besenfelder U, Mokry M, Vos PLAM, Stout TAE, Le Gac S, Gadella BM. An oviduct-on-a-chip provides an enhanced in vitro environment for zygote genome reprogramming. Nat Commun. 2018;9:4934. doi: 10.1038/s41467-018-07119-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93. Wang M, Zhu T, Liu C, Jin L, Fei P, Zhang B. Oviduct‑mimicking microfluidic chips decreased the ROS concentration in the in vitro fertilized embryos of CD‑1 mice. Biomed Pharmacother. 2022;154:113567. doi: 10.1016/j.biopha.2022.113567. [DOI] [PubMed] [Google Scholar]
- 94. Yu H, Gao R, Liu Y, Fu L, Zhou J, Li L. Stimulus‑responsive hydrogels as drug delivery systems for inflammation targeted therapy. Adv Sci. 2024;11(1):e2306152. doi: 10.1002/advs.202306152. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 95. Tsevat DG, Wiesenfeld HC, Parks C, Peipert JF. Sexually transmitted diseases and infertility. Am J Obstet Gynecol. 2017;216(1):1–9. doi: 10.1016/j.ajog.2016.08.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96. Jenkins SM, Vadakekut ES. Pelvic inflammatory disease. Treasure Island (FL): StatPearls Publishing; 2025. https://www.ncbi.nlm.nih.gov/books/NBK499959/ [accessed 2025 Jun 2]. [PubMed] [Google Scholar]
- 97. Hill CJ, Fakhreldin M, Maclean A, Dobson L, Nancarrow L, Bradfield A, Choi F, Daley D, Tempest N, Hapangama DK. Endometriosis and the uterine tubes: theories of origin and clinical implications. J. Clin. Med. 2020;9:1905. doi: 10.3390/jcm9061905 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 98. Ambildhuke K, Pajai S, Chimegave A, Mundhada R, Kabra P. A review of tubal factors affecting fertility and its management. Cureus. 2022;14(11):e30990. doi: 10.7759/cureus.30990. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99. Ghahremani-Nasab M, Babaie S, Bazdar S, et al. Infertility treatment using polysaccharides-based hydrogels: new strategies in tissue engineering and regenerative medicine. J Nanobiotechnology. 2025;23(1):162. doi: 10.1186/s12951-025-03267-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 100. Dhlamini KS, Selepe CT, Ramalapa B, Tshweu L, Ray SS. Reimagining chitosan-based antimicrobial biomaterials to mitigate antibiotic resistance and alleviate antibiotic overuse: a review. Macromol. Mater. Eng. 2024;309:2400018. doi: 10.1002/mame.202400018. [DOI] [Google Scholar]
- 101. Alghofaily M, Almana A, Alrayes J, Lambarte R, Weir MD, Alsalleeh F. Chitosan–gelatin scaffolds loaded with different antibiotic formulations for regenerative endodontic procedures promote biocompatibility and antibacterial activity. J Funct Biomater. 2024;15(7):186. doi: 10.3390/jfb15070186. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 102. Hemmingsen LM, Škalko-Basnet N, Jøraholmen MW. The expanded role of chitosan in localized antimicrobial therapy. Mar Drugs. 2021;19(12):697. doi: 10.3390/md19120697. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103. Tsoumanis A, Van Dijck C, Hens N, Kenyon C. Switching from dual to monotherapy for gonorrhea is associated with a halving of gonococcal resistance to azithromycin-a modelling study of MSM in Belgium. Open Forum Infect Dis. 2025;12(6):ofaf320. doi: 10.1093/ofid/ofaf320. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 104. White JA, Dukers-Muijrers NH, Hoebe CJ, Kenyon CR, Dc Ross J, Unemo M. 2025 European guideline on the management of Chlamydia trachomatis infections. Int J STD AIDS. 2025;36(6):434–49. doi: 10.1177/09564624251323678. [DOI] [PubMed] [Google Scholar]
- 105. Divakar P, Caruso I, Moodie KL, Theiler RN, Hoopes PJ, Wegst UGK. Design, manufacture, and in vivo testing of a tissue scaffold for permanent female sterilization by tubal occlusion. MRS Adv. 2018;3(30):1685–90. doi: 10.1557/adv.2018.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 106. Vecchietti LF, Wijaya BN, Armanuly A, Hangeldiyev B, Jung H, Lee S, Cha M, Kim HM. Artificial intelligence-driven computational methods for antibody design and optimization. MAbs. 2025;17(1):2528902. doi: 10.1080/19420862.2025.2528902. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 107. Shaik N, Shaik A. Advancing AI‑driven tissue engineering constructs through future directions in real‑time adaptation, multi‑modal integration, and personalized scaffold design. ShodhKosh J Vis Perform Arts. 2023;4(1):1624–33. doi: 10.29121/shodhkosh.v4.i1.2023.4124 [DOI] [Google Scholar]



